Menopause has a beneficial influence on the evolution of prolactinomas. A study of 99 patients
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Menopause benefits women with prolactinoma, aiding dopamine agonist withdrawal. Most post-menopausal women achieve sustained remission after stopping treatment, with few experiencing mild recurrences.
Area Of Science
- Endocrinology
- Reproductive Medicine
- Oncology
Background
- Prolactinoma management often involves dopamine agonist (DA) therapy.
- Menopause is hypothesized to improve prolactinoma outcomes and facilitate DA withdrawal.
- Limited evidence currently supports the beneficial role of menopause in prolactinoma treatment.
Purpose Of The Study
- To investigate the impact of menopause on prolactinoma progression.
- To assess the rate of prolactinoma recurrence after dopamine agonist withdrawal in post-menopausal women.
Main Methods
- Retrospective analysis of 99 women with prolactinoma treated with dopamine agonists.
- Data collected from two tertiary academic hospitals.
- Menopause defined by amenorrhea and hormonal criteria; tumor characteristics recorded.
Main Results
- Significant reductions in prolactin levels and tumor size observed post-menopause in women on stable DA doses.
- Dopamine agonist treatment was successfully discontinued in 56 women (57%), with 73% achieving sustained remission.
- Recurrence occurred in 27% of women, primarily within the first year, with early post-withdrawal prolactin levels predicting recurrence.
Conclusions
- Menopause positively influences prolactinoma evolution and aids in successful dopamine agonist withdrawal.
- Two-thirds of eligible post-menopausal women can achieve sustained remission.
- Recurrences post-withdrawal are typically mild and asymptomatic.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Menopause, a natural biological process marking the end of a woman's fertility, typically occurs between the fifth and sixth decade of life. This phase is characterized by the exhaustion of the ovarian follicle pool, leading to less responsive ovaries despite the high levels of Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH). The consequential decrease in estrogen production results in symptoms like hot flashes, heavy sweating, headaches, hair loss, muscle pains, vaginal...
The ovarian cycle regulates endometrial changes throughout a single menstrual cycle via the coordinated action of gonadotrophin-releasing hormone (GnRH) and gonadotrophins.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
In human women, oogenesis produces one mature egg cell or ovum for every precursor cell that enters meiosis. This process differs in two unique ways from the equivalent procedure of spermatogenesis in males. First, meiotic divisions during oogenesis are asymmetric, meaning that a large oocyte (containing most of the cytoplasm) and minor polar body are produced as a result of meiosis I, and again following meiosis II. Since only oocytes will go on to form embryos if fertilized, this unequal...
Puberty is a critical phase, typically beginning between the ages of 8 and 13 in girls and 9 and 14 in boys, though timing can vary based on genetics, environmental factors, and overall health. This period is characterized by the development of secondary sexual characteristics and the attainment of reproductive potential. Endocrine changes underpin puberty, with hormonal surges of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH) instigated by Gonadotropin-Releasing Hormone (GnRH)...
The female reproductive system can be affected by several disorders, including Premenstrual Syndrome (PMS), Premenstrual Dysphoric Disorder (PMDD), endometriosis, and various forms of cancer. PMS and PMDD are cyclical conditions that cause physical and emotional distress, with symptoms that include edema, mood swings, and food cravings. PMDD is a more severe form of PMS characterized by increased symptom severity that peaks during the luteal phase and tends to improve or resolve shortly after...
The ovarian cycle is meticulously regulated by the hypothalamic-pituitary-gonadal axis. This cycle orchestrates the release of a mature oocyte, essential for reproduction.
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...